Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
VANCOUVER, Cardiome
Pharma Corp. today announced that its Chinese development and commercialization
partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to
support regulatory approval in China. The study will be conducted in
healthy volunteers. Other details of the study were not disclosed. If BRINAVESS
successfully completes Phase 1, Eddingpharm anticipates initiating a pivotal
Phase 3 study by year end.
"We are pleased that Eddingpharm is taking the first steps necessary to gain approval of BRINAVESS inChina", said William Hunter, M.D., CEO and Director of Cardiome. "The Chinese market is an important growth driver for BRINAVESS given the region's size and demand for innovative medicines, and Eddingpharm is the perfect partner for Cardiome. Cardiome remains committed to have BRINAVESS available for all patients suffering from atrial fibrillation worldwide."
Cardiome and Eddingpharm entered into a BRINAVESS development and commercialzation agreement inChina, Taiwan, Macau and Hong Kong on December 19, 2014.
Source: Cardiome Pharma Corp.
Comments